(R)-BEL is an irreversible, chiral, mechanism-based inhibitor of iPLA2γ (IC50 ~ 0.6 μM). Unlike (S)-BEL, (R)-BEL does not inhibit iPLA2β except at high doses (20-30 μM).
1. Balsinde, J., et al., 1999. Regulation and inhibition of phospholipase A2. Annual review of pharmacology and toxicology. 39(): 175-89. PMID: 10331081
2. Jenkins, Christopher M., et al., 2002. Identification of calcium-independent phospholipase A2 (iPLA2) beta, and not iPLA2gamma, as the mediator of arginine vasopressin-induced arachidonic acid release in A-10 smooth muscle cells. Enantioselective mechanism-based discrimination of mammalian iPLA2s. The Journal of biological chemistry. 277(36): 32807-14. PMID: 12089145
圣克鲁斯生物技术在生物医药研究市场的产品开发方面处于世界领先地位。欢迎 致电我们的免费电话(021) 800-820-8626。 版权 ©, 2007-2021圣克鲁斯生物技术。版权所有。“Santa Cruz Biotechnology”,圣克鲁斯生物技 术的 商标,“Santa Cruz Animal Health”,“San Juan Ranch”,“Supplement of Champions”,San Juan Ranch的商标,“Ultracruz”,“Chemcruz”,“Immunocruz”,“Exactacruz”和“EZ Touch”都是圣克鲁斯生物技术的注册商标。所有的商标都归其各自拥有者所有。